Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 4/20 | 0.36 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.36 |
| ▸ | USP2 | O75604 | 2/20 | 0.36 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | CNR1 | P21554 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Isopropylamine SCHEMBL28680220 | 0.93 | MEN1 (0.40) | TSHRMEN1KMT2ALMNAADRA1A | |
| Trichloroacetic Acid SCHEMBL28670920 | 0.87 | TSHR (0.42) | TSHRMEN1KMT2ALMNAADRA1A | |
| Trichloroacetic Acid SCHEMBL28665553 | 0.87 | TSHR (0.42) | TSHRMEN1KMT2ALMNAADRA1A | |
| SCHEMBL9243012 | 0.83 | TSHR (0.46) | TSHRMEN1KMT2ALMNAADRA1A | |
| SCHEMBL9412783 | 0.81 | TSHR (0.43) | TSHRMEN1KMT2ALMNAADRA1A | |
| SCHEMBL7655973 | 0.79 | TSHR (0.42) | TSHRMEN1KMT2ALMNAADRA1A | |
| SCHEMBL5244967 | 0.77 | MEN1 (0.40) | TSHRMEN1KMT2ALMNAADRA1A | |
| Ammonia Solution, Strong SCHEMBL624387 | 0.77 | MEN1 (0.40) | TSHRMEN1KMT2ALMNAADRA1A | |
| SCHEMBL11345569 | 0.75 | MAPT (0.33) | TSHRLMNAMAPTTP53 | |
| SCHEMBL11853880 | 0.75 | MEN1 (0.39) | TSHRMEN1KMT2ALMNAADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105646757-A | Cationic polymerization system and preparation method of high-unsaturation-degree isoolefin copolymer | 中国石油化工股份有限公司 | 2016-06-08 | — | — | CN | claimed |
| US-11813278-B2 | Highly active compounds against COVID-19 | Atea Pharmaceuticals, Inc. (US) | 2023-11-14 | — | — | US | disclosed |
| US-11813278-B2 | Highly active compounds against COVID-19 | Atea Pharmaceuticals, Inc. (US) | 2023-11-14 | — | — | US | disclosed |
| EP-4234565-A2 | HIGHLY ACTIVE COMPOUNDS AGAINST COVID-19 | ATEA Pharmaceuticals, Inc. (US) | 2023-08-30 | — | — | EP | disclosed |
| US-11738038-B2 | Highly active compounds against COVID-19 | Atea Pharmaceuticals, Inc. (US) | 2023-08-29 | — | — | US | disclosed |
| US-11738038-B2 | Highly active compounds against COVID-19 | Atea Pharmaceuticals, Inc. (US) | 2023-08-29 | — | — | US | disclosed |
| US-11738038-B2 | Highly active compounds against COVID-19 | Atea Pharmaceuticals, Inc. (US) | 2023-08-29 | — | — | US | disclosed |
| CN-114391017-A | Glycerol-mannose-heptose phosphate derivatives and their use for modulating immune response | 上海药苑生物科技有限公司 | 2022-04-22 | — | — | CN | disclosed |
| CN-113950245-A | Herbicidal composition | 石原产业株式会社 | 2022-01-18 | — | — | CN | disclosed |
| CN-113873887-A | Herbicidal composition | 石原产业株式会社 | 2021-12-31 | — | — | CN | disclosed |
| CN-102459354-B | Photosensitive composition | SANYO CHEMICAL IND LTD | 2014-08-20 | — | — | CN | disclosed |
| US-20140045966-A1 | PHOTOSENSITIVE COMPOSITION. CURED ARTICLE, AND METHOD FOR PRODUCING ACTINICALLY CURED ARTICLE | SANYO CHEMICAL INDUSTRIES, LTD. (JP) | 2014-02-13 | — | — | US | disclosed |
| CN-103176360-A | Photosensitive composition | SANYO CHEMICAL IND LTD | 2013-06-26 | — | — | CN | disclosed |
| US-20120142967-A1 | PROCESSES FOR THE PREPARATION OF 5-HT2C RECEPTOR AGONISTS | ARENA PHARMACEUTICALS, INC. | 2012-06-07 | — | — | US | disclosed |
| US-20120142806-A1 | PHOTOSENSITIVE COMPOSITION | SANYO CHEMICAL INDUSTRIES, LTD. (JP) | 2012-06-07 | — | — | US | disclosed |
| EP-2443080-A2 | PROCESS FOR THE PREPARATION OF 5-HT2C RECEPTOR AGONISTS | Arena Pharmaceuticals, Inc. (US) | 2012-04-25 | — | — | EP | disclosed |
| EP-2441778-A1 | PHOTOSENSITIVE COMPOSITION | Sanyo Chemical Industries, Ltd. (JP) | 2012-04-18 | — | — | EP | disclosed |
| WO-2010148207-A2 | PROCESSES FOR THE PREPARATION OF 5-HT2C RECEPTOR AGONISTS | ARENA PHARMACEUTICALS, INC. (US) | 2010-12-23 | — | — | WO | disclosed |
| US-4845278-A | Crosslinkable aramids | ERHAN SEMIH (US) | 1989-07-04 | — | — | US | disclosed |
| US-4293440-A | HALOGENATED ALDEHYDE, SULFONATE, OR CARBOXYLATE | HALLIBURTON COMPANY (US) | 1981-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142967-A1 | PROCESSES FOR THE PREPARATION OF 5-HT2C RECEPTOR AGONISTS | HTR2C, HTR3C, HTR5A | TSHR 302/4885MEN1 2296/4885KMT2A 652/4885 |
| US-11813278-B2 | Highly active compounds against COVID-19 | PNP, ACE2, MTAP | TSHR 4724/4885MEN1 4130/4885KMT2A 2357/4885 |
| US-11738038-B2 | Highly active compounds against COVID-19 | PNP, ACE2, MTAP | TSHR 4724/4885MEN1 4130/4885KMT2A 2357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.